The availability of IL-1-targeting agents unveiled the pathophysiological role of IL-1-mediated inflammation in a wide range of disorders beyond the spectrum of CIRDs, including T2D and CVD which are frequent comorbidities in rheumatic patients [154]. The gene discussed is IL1A; the disease is type 2 diabetes mellitus.